Document:

EX-10.8

 Exhibit 10.8 

SENTI BIOSCIENCES, INC. 

EMPLOYMENT AGREEMENT 
 (Curt
A. Herberts III) 
 This Employment Agreement (this “Agreement”) dated as of April 28, 2018 (the “Effective
Date”), is made by and between Senti Biosciences, Inc., a Delaware corporation (the “Company”), and Curt A. Herberts III (“Executive”). 

WHEREAS, the Company wishes to employ Executive, and Executive wishes to be employed by the Company, upon the terms and conditions set forth
herein. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, the parties hereto
agree as follows: 
 1. Start Date. This Agreement will be binding and in full force and effect as of the Effective Date.
Executive’s first date of employment (the “Start Date”) will be determined by agreement of the parties, but shall be no later than June 4, 2018. 

2. Title and Responsibilities. The Company hereby employs Executive to perform those executive duties and services as the Chief
Executive Officer of the Company (the “CEO”) shall assign to him from time to time, and Executive accepts employment with the Company, upon the terms and conditions hereinafter set forth. Executive shall serve as the Chief Financial
Officer and the Chief Business Officer of the Company and shall report to the CEO. The CEO shall have the right to review and change the responsibilities of Executive from time to time as he may deem necessary or appropriate. 

3. Duty to Perform Services. Commencing on the Start Date, except as provided below. Executive shall devote his full business time to
rendering services to the Company hereunder, and shall exert all reasonable efforts in the rendering of such services. Except to the extent the restrictions contained in Section 11 may apply, nothing in this Agreement shall prohibit Executive
from (a) making and managing passive investments, or (b) participating in professional and charitable organizations in an unpaid capacity, in a manner, and to an extent that will not interfere with his duties to the Company. In addition,
Executive will be allowed to be a member of the board of directors for up to two (2) companies, provided that such activities are not competitive to the Company and are approved in advance in writing by the Company, which approval shall not be
unreasonably withheld. Executive agrees that in the rendering of all services to the Company and in all aspects of employment hereunder, he shall comply in all material respects with all directives, policies, standards and regulations from time to
time established by the Company. The Company reserves the right to alter, supplement or rescind its employment procedures, benefits or policies at any time in its sole and absolute discretion and without notice. It is agreed that in the first month
of each calendar year, the CEO and Executive will meet to discuss Executive’s performance during the preceding year, and compensation, benefits and equity for the new calendar year, to ensure that the Company’s and Executive’s
expectations remain properly aligned. 
 4. Term of Agreement. The term of this Agreement will commence on the Effective Date. There
shall be no definite term of employment, and Executive shall be an employee at will. This Agreement will terminate upon the occurrence of a “Termination Event” subject to, and in accordance with, Section 14, or earlier termination
pursuant to Section 15. 

 5. Compensation. 

(a) Base Salary. During the term of this Agreement, the Company shall pay Executive an annual base salary (the “Base
Salary”), payable in equal installments in accordance with the Company’s standard schedule for salary payments to its employees, at an initial annual rate equal to $370,000. Executive’s Base Salary shall be reviewed annually by
the Company’s board of directors (the “Board”), commencing in January 2019 and may be adjusted by the Company after each such review after discussions between the Company and Executive. 

(b) Cash Bonuses. 
 (i)
Signing Bonus. Promptly after the Start Date, the Company shall pay Executive a cash bonus of $100,000. 
 (ii) Annual Performance
Bonus. For each calendar year during the term of this Agreement, including 2018, Executive shall be eligible to receive an annual performance bonus (the “Annual Bonus”) with a target amount of 35% of the base salary received by
Executive during such year, contingent upon satisfaction of performance goals, which shall be determined by the Company at the beginning of each calendar year after consultation with Executive. One or more performance goals will be based upon the
performance of the Company and one or more performance goals will be based more directly upon Executive’s performance. Any Annual Bonus shall be paid within 90 days after the end of the calendar year to which the performance goals relate and
shall be subject to Executive serving as the Chief Financial Officer and Chief Business Officer of the Company on the last day of such year; provided, however, that if Executive’s employment is terminated prior to the last day of
such year without Cause or he resigns for Good Reason, then Executive will receive a pro-rata of his target bonus based on the number of days employed during the applicable bonus year. 

(c) Stock. 
 (i) Stock
Option. Promptly after the Start Date, and subject to the Board’s approval, the Company shall grant to Executive an incentive stock option (the “Option”) under the Company s 2015 Stock Incentive Plan (the
“Plan”) to purchase 1,070,964 shares (“Option Shares”) of the Company’s common stock, $0.0001 par value per share (“Common Stock”), at an exercise price equal to the fair value per share as of
the Grant Date. The Company represents that the Option Shares represent, as of the Effective Date, 2.0% of the Company’s Fully Diluted Shares Outstanding (as defined below). The Option shall be subject to vesting such that 25% of the Option
Shares shall become vested on upon the first anniversary of the Start Date and the remainder shall vest in equal monthly portions over the following 36 months, for a total four-year vesting period; provided, however, that 100% of the
Option Shares shall become vested if and when Executive’s employment is terminated by the Company (or its successor) within 3 months prior to or 12 months after a Change of Control, or if he terminates it for Good Reason within 3 months prior
to or 12 months after a Change of Control. “Fully Diluted Shares Outstanding” for purposes of this paragraph means the total number of shares of outstanding Company Common Stock and Company Preferred Stock, with the Preferred Stock
calculated on an as-converted to Common Stock basis, including for this purpose the maximum number of shares issuable under the Company’s outstanding options, warrants, convertible notes and other rights to acquire capital stock of the Company
and all shares remaining available for issuance under the Plan and any other equity incentive plan of the Company. 

  
 2 

 6. Vacation; Holidays and Sick Time; Benefits. 

(a) Vacation. Executive shall be entitled to three weeks of vacation during each calendar year of this Agreement, pro-rated for any
partial years. Vacation days accrued but not used by the end of any calendar year may be used in the subsequent calendar year. 
 (b)
Holidays and Sick Time. Executive shall be entitled to paid legal and religious holidays and sick days in accordance with the Company’s normal policies in effect from time to time. 

(c) Benefits. Subject to any contribution therefor generally required of executive employees of the Company, commencing on the Start
Date, Executive shall be entitled to participate in any and all employee benefit plans from time to time in effect for the full-time executive employees of the Company generally (collectively, the “Benefit Plans”), but the Company
shall not be required to establish any such program or plan. Such participation shall be subject to (i) the terms of the applicable plan documents, and (ii) generally applicable Company policies. The Company may alter, modify, add to or
delete its employee Benefit Plans at any time as it, in its sole discretion, determines to be appropriate. 
 7. Expenses. The Company
shall pay or reimburse Executive for all reasonable business expenses incurred or paid by Executive in connection with his employment by the Company in accordance with the Company’s policies in effect from time to time. 

8. Confidential Information. 

(a) Executive understands that the Company continually obtains and develops valuable proprietary and confidential information concerning its
scientific or business affairs (the “Confidential Information”) which may become known to him in connection with his employment by the Company. 

(b) Executive acknowledges that all Confidential Information, whether or not in writing and whether or not labeled or identified as
confidential or proprietary, is and shall remain the exclusive property of the Company or the third party providing such information to Executive or the Company. By way of illustration, but not limitation, Confidential Information may include
Inventions (as defined in Section 9(a)), trade secrets, technical information, knowhow, research and development activities of the Company, product and marketing plans, customer and supplier information and information disclosed to the Company
or to him by third parties of a proprietary or confidential nature or under an obligation of confidence. Confidential Information is contained in various media, including without limitation, patent applications, research data and observations,
records of clinical trials, computer programs in object and/or source code, technical specifications, laboratory notebooks, supplier and customer lists, internal financial data and other documents and records of the Company. 

  
 3 

 (c) Executive agrees that Executive shall not, during the term of his engagement by the
Company and thereafter, publish, disclose or otherwise make available to any third party any Confidential Information except as expressly authorized herein or in writing by the Company. Executive may disclose Confidential Information to
(i) directors, employees, consultants and representatives of the Company, to (ii) accountants, financial advisors and counsel of Executive, who have a bona fide need to know such information and who are bound by an obligation not to use or
disclose such information without authorization from the Company and to (iii) other parties that enter into confidentiality or non-disclosure agreements with the Company and to whom such Confidential Information will be disclosed for legitimate
business purposes of the Company. Executive agrees that Executive shall use such Confidential Information only in the performance of his duties for the Company and in accordance with any Company policies with respect to the protection of
Confidential Information. Executive agrees not to use such Confidential Information for his own benefit or for the benefit of any other person or business entity. 

(d) Executive agrees to exercise all reasonable precautions to protect the integrity and confidentiality of Confidential Information in his
possession and not to remove any materials containing Confidential Information from the Company’s premises except to the extent necessary to him employment for the benefit of the Company. 

(e) Upon the termination of his employment by the Company, or at any time upon the Company s request, Executive shall return immediately to the
Company any and all tangible materials containing any Confidential Information then in his possession or under his control and destroy any intangible copies of such Confidential Information. Executive may not access or store any Confidential
Information of the Company except in accordance with Company’s policies. If Executive stores any Confidential Information on a computer (including a tablet or smartphone) that is not owned by the Company, then Executive shall delete and/or
return such Confidential Information from such devices upon termination of his employment. 
 (f) Notwithstanding anything to the contrary in
this Agreement or any other agreement between the Executive and the Company, the Executive understands that nothing m this Agreement or any other agreement between the Executive and the Company prohibits, or is intended in any manner to prohibit,
the Executive from reporting possible violations of federal law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency
Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. The Executive does not need the prior authorization of anyone at the Company or the Company’s legal counsel to
make any such reports or disclosures, and the Executive is not required to notify the Company that the Executive has made such reports or disclosures. 

(g) Confidential Information shall not include information which (i) is or becomes generally known within the Company’s industry or
otherwise through no fault of Executive; (ii) was known to him prior to the Start Date and/or at the time it was disclosed (as evidenced by his written records at the time of disclosure); or (iii) is lawfully and in good faith made
available to him by a third party who did not derive it from the Company and who imposes no obligation of confidence on Executive. 

  
 4 

 9. Ownership and Assignment of Inventions. 

(a) Executive agrees promptly to disclose to the Company any and all ideas, concepts, discoveries, inventions, developments, trade secrets,
methods, data, information, improvements, chemical or biological materials and know-how that are conceived, devised, invented, developed or reduced to practice or tangible medium by Executive, under his direction or jointly with others during any
period that Executive is employed by the Company, whether or not during normal working hours or on the premises of the Company (hereinafter “Inventions”). 

(b) Executive hereby assigns to the Company all of his right, title and interest to the Inventions and any and all related patent rights,
copyrights and applications and registrations therefor. During and after his employment by the Company, Executive shall cooperate with the Company, at the Company’s expense, in obtaining proprietary protection for the Inventions and Executive
shall execute all documents which the Company shall reasonably request in order to perfect the Company’s rights in the Inventions. Executive hereby appoints the Company his attorney-in-fact to execute and deliver any such documents on his
behalf in the event Executive should fail or refuse to do so within a reasonable period following the Company’s request. It is understood that reasonable out-of-pocket expenses of Executive’s assistance incurred at the request of the
Company under this Section will be reimbursed by the Company. 
 (c) Executive represents that the attached Schedule A contains a
complete list, as of the Effective Date, of all inventions that are currently owned by Executive, alone or jointly with others, and which have not been assigned to prior employers or clients and which are not assigned to the Company hereunder
(“Prior Inventions”). If there is no such Schedule A attached hereto, Executive represents that there are no such Prior Inventions. 

(d) Notwithstanding anything the foregoing, in accordance with California Labor Code Sections 2870-2872,1 acknowledge that this Agreement does
not require me to assign to the Company any invention that was developed entirely on my own time without using the Company s equipment, supplies, facilities, or trade secret information of the Company (except for those inventions that either
(i) relate at the time of conception or reduction to practice of the invention to the business of the Company or to the Company’s actual or demonstrably anticipated research or development, or (ii) result from any work performed by me
for the Company), and that this Agreement constitutes written notice from the Company that this Agreement does not apply to an invention which qualifies fully under the provisions of California Labor Code Section 2870. 

10. Other Obligations. 

(a) Between Executive and Third Parties. Executive hereby represents, warrants and agrees (i) that Executive has the full right to
enter into this Agreement and perform the services required of him hereunder, without any restriction whatsoever; (ii) that in the course of performing services hereunder, Executive will not violate the terms or conditions of any agreement
between him and any third party, including former employers and clients, or infringe or wrongfully appropriate any patents, copyrights, trade secrets or other intellectual property rights of any Person anywhere in the world; (iii) that
Executive has not and will not disclose or use during his employment by the Company any confidential information that he acquired as a result of any previous employment or consulting arrangement or under a previous obligation of confidentiality; and
(iv) that Executive has disclosed to the Company in writing any and all continuing obligations to previous employers or others that require his not to disclose any information to the Company. 

  
 5 

 (b) Between the Company and Third Parties. Executive acknowledges that the Company
from time to time may have agreements with other Persons, including the government of the United States or other countries and agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of
work thereunder or regarding the confidential nature of such work. Executive agrees to be bound by all such obligations and restrictions and to take all action necessary to discharge the obligations of the Company thereunder. 

11. Exclusive Commitment. Executive agrees that during the period of his employment by the Company and for a period of 12 months after
termination or cessation of such employment for any reason (the “Restricted Period”), Executive shall not, without the Company’s prior written consent, provide services, as a principal, officer, director, employee or
consultant, or be a member or partner of, or hold more than one percent (1%) of the outstanding capital stock of, any business enterprise that dedicates a significant amount of resources to the Field of Interest (as defined in Section 16).
This Section 11 shall not apply for so long as Executive resides, or primarily provides the services to the Company, in the State of California. 

12. General Non-Solicitation. Executive agrees that during the Restricted Period, Executive shall not solicit, divert or take away, or
attempt to divert or take away, the business or patronage of any of the clients, customers or accounts, or prospective clients, customers or accounts, of the Company which were contacted, solicited or served by him while employed by the Company.
This Section 12 shall not apply for so long as Executive resides, or primarily provides the services to the Company, in the State of California. 

13. Non-Solicitation of Employees. Executive agrees during the Restricted Period, Executive shall not directly or indirectly
(i) recruit or solicit any employee of the Company, or induce or attempt to induce any employee to discontinue his or his employment relationship with the Company or (ii) without the written consent of the Company, solicit or recruit any
consultant then actively engaged by the Company to perform services in the Field of Interest. 
 14. Termination Without Severance.

 (a) Termination Events. The following events shall each be considered a “Termination Event” and, upon the
occurrence of any of them, shall have the effect of immediately terminating the Company’s obligations under this Agreement, including its obligation to make any further payments hereunder but excluding: (1) the payment of base salary which
is accrued at the date of termination; (2) the dollar equivalent for Executive’s accrued and untaken vacation days as of the date of termination; (3) reimbursement for any unreimbursed expenses incurred through the date of
termination; and (4) any unpaid bonus for any completed prior fiscal year payable when it otherwise would have been paid: 

  
 6 

 (i) Executive’s death; 

(ii) Executive’s Disability for such period of time and under circumstances which would constitute a Permanent Disability (as defined in
Section 16); 
 (iii) The termination of Executive’s employment by the Company for Cause (as defined in Section 16); or 

(iv) The termination of Executive’s employment by Executive without Good Reason. 

(b) Termination for Cause. To the extent practicable, any decision to terminate Executive’s employment for Cause shall be made by
the President after Executive has received notice from the Company including details of the grounds for termination for Cause. Termination pursuant to Section 14(a)(iii) shall be without prejudice to any other right or remedy to which the
Company may be entitled, at law, in equity, under this Agreement or otherwise. 
 (c) Notice of Termination. Executive agrees to
provide the Company with a notice of termination thirty (30) days prior to the effective date of a termination pursuant to Section 14(a)(iv). 

(d) Survival. Notwithstanding Executive’s termination of employment pursuant to Section 14(a)(ii), 14(a)(iii) or 14(a)(iv),
Executive’s covenants and obligations set forth in Sections 8, 9, 11, 12, 13, 14(d), 16 and 17 shall remain in effect and be fully enforceable in accordance with the provisions thereof. 

15. Termination With Severance. 

(a) Right to Terminate; Notice. In addition to the other termination rights provided to the Company or Executive hereunder, the Company
may terminate Executive’s employment without Cause and Executive may terminate Executive’s employment for Good Reason. 
 (b)
Survival. In the event that Executive’s employment is terminated by the Company without Cause, or by Executive for Good Reason, then Executive ,s covenants and obligations set forth in Sections 8, 9, 11, 12, 13, 14(d), 16 and 17 shall
remain in effect and be fully enforceable in accordance with the provisions thereunder. 

  
 7 

 (c) Severance. In the event that Executive’s employment is terminated by the
Company without Cause, or by Executive for Good Reason, then, subject to Section 15(d), Executive shall be entitled to receive (i) the installments of base salary set forth in Section 5(a) not yet paid to Executive, payable when and
as if Executive had continued to be employed by the Company until the Severance Expiration Date (as defined in Section 16); (ii) the dollar equivalent for Executive’s accrued and untaken vacation days as of the date of termination,
(iii) any unpaid bonus for any completed prior fiscal year when it otherwise would have been paid, (iv) reimbursement for any unreimbursed expenses incurred through the date of termination; and (v) if Executive elects to maintain
medical insurance coverage under COBRA, then Company shall pay Executive, concurrent with any payments made pursuant to clause (i) above, reimbursement for Executive’s (and his family’s) COBRA premiums through the Severance Expiration
Date. Nothing in this Section 15(c) shall be construed as imposing any obligation on the Company to maintain medical insurance benefits of any nature at any time. Payments otherwise scheduled to be made under this Section 15(c) prior to
the effective date of the release in Section 15(d) (namely, the date it can no longer be revoked) shall accrue and be paid on the first payroll date that follows such effective date with subsequent payments occurring on each subsequent Company
payroll date; provided, however, that if the period during which Executive may sign the release under Section 15(d) begins in one calendar year and ends in a second calendar year, then the payments provided in this Section 15(c) shall not
be paid or the first payment shall not occur until the first payroll date in the second calendar year. 
 (d) Release; Termination of
Severance. Notwithstanding anything to the contrary in Section 15(c), Executive shall not be entitled to receive any payments or benefits pursuant to Section 15(c) unless he first executes and delivers to the Company a general release
in the form attached hereto as Exhibit A. Without prejudice to any other right or remedy to which the Company may be entitled, the Company may terminate its obligations under Section 15(c) if Executive breaches his obligations under Sections 8,
9, 11, 12 or 13. 
 16. Certain Definitions. For purposes of this Agreement, the following terms shall have the meanings set forth
below: 
 “Cause” means the occurrence of any of the following: (a) Executive’s material breach of this
Agreement, (b) any act (other than retirement) or omission by the Executive which has a material and adverse effect on the Company’s business, or on Executive’s ability to perform services for the Company, including, without
limitation, the commission of any crime (other than minor traffic violations), or (c) Executive’s material misconduct or material neglect of his duties in connection with the business or affairs of the Company; provided,
however, that before terminating Executive’s employment for Cause, the Company will (i) provide Executive with 30 days’ advance written notice with the event specifically set forth in the notice and the opportunity to cure the
event (if curable), (ii) provide Executive a reasonable opportunity to present his case to the Board, and (iii) require that the Board determine, by majority vote, whether Executive’s employment should be terminated for Cause. 

“Change of Control” means the closing of (i) a sale of all or substantially all of the assets of the Company, (ii) any
consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the stockholders of the Company
immediately prior to such consolidation, merger or reorganization, continue to hold a majority of the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation,
merger or reorganization; or (iii) a stock tender or a merger, consolidation or similar event pursuant to a transaction or series of related transactions in which a third party (which term shall include a current stockholder) acquires more than
fifty percent (50%) of the equity voting securities of the Company outstanding immediately prior to the consummation of such transaction or series of related transactions, and the shareholders of the Company do not retain a majority of the
equity voting securities of the surviving entity, other than (a) a merger, conversion or other transaction the principal goal of which is to change the jurisdiction of incorporation of the Company, or (b) an equity security financing for
the account of the Company in which capital stock of the Company is sold to one or more institutional investors. 

  
 8 

 “Disability” means the inability of Executive to substantially perform his
duties to the Company as a result of his incapacity due to illness or physical disability. 
 “Field of Interest” means the
discovery, development or commercialization of medical products being developed or produced by the Company that: (i) can be administered to a subject; and (ii) can cause an affected cell or tissue of mammalian (or human) origin to detect
the presence or absence of certain molecules; and/or (iii) can cause an affected cell or tissue of mammalian (or human) origin to synthesize certain other molecules. Without limiting the generality of the foregoing, this is also known as the
field of adaptive medicine or mammalian synthetic biology. 
 “Good Reason” means Executive’s termination of his
employment because of (i) the Company’s breach of any one or more of the material provisions of this Agreement; (ii) a material reduction by the Company of Executive’s Base Salary, unless Executive consents to such reduction or
unless such reduction is applied equally, as a percentage of base salary, to all senior executives of the Company; (iii) a relocation of the Company’s location such that Executive’s one-way commute as of the Start Date increases by
more than 35 miles or (iv) a material adverse change in Executive’s duties, authority, or responsibilities relative to Executive’s duties, authority, or responsibilities in effect immediately prior to such reduction (other than a
change in title and provided that a change in title, reporting lines or position in connection with a Change of Control will not, in itself, be deemed to be a change in duties, authority or responsibility); provided, however, that any
such termination by Executive shall only be deemed for Good Reason pursuant to this definition if: (1) Executive gives the Company written notice of his intent to terminate for Good Reason within ninety (90) days following the first
occurrence of the condition(s) that he believes constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice
(the “Cure Period”); and (3) Executive voluntarily terminates his employment within thirty (30) days following the end of the Cure Period. 

“Permanent Disability” means a Disability which continues for at least 120 consecutive calendar days or ISO calendar days
during any consecutive twelve-month period, after its commencement, and its determined in good faith to be total and permanent by the Board following consultation with reputable medical or health experts selected by the Board. 

“Person” means an individual, a corporation, an association, a partnership, an estate, a trust and any other entity or
organization. 
 “Severance Expiration Date” means the date that is nine months after the date of termination of
employment. 
 17. Miscellaneous. 

(a) Entire Agreement; No Representations or Warranties. This Agreement constitutes the entire agreement among the parties with respect
to the subject matter hereof and supersedes all other prior agreements and understandings, both written and oral, between the parties with respect to such subject matter. Executive acknowledges and agrees that, in accepting employment with the
Company, he has not relied upon any agreements or representations not expressly set forth herein. 

  
 9 

 (b) Assignability. This Agreement shall be binding upon and inure to the benefit of
the parties hereto and their respective successors and permitted assigns. This Agreement is not intended to confer upon any Person other than the parties hereto any rights or remedies hereunder, except as otherwise expressly provided herein and
shall not be assignable by operation of law or otherwise. 
 (c) Amendments and Supplements. This Agreement may not be altered,
changed or amended, except by an instrument in writing signed by the parties hereto; provided, however, that no such alteration, change or amendment may be binding on the Company unless approved by the Board. 

(d) No Waiver. The terms and conditions of this Agreement may be waived only by a written instrument signed by the party waiving
compliance. In the case of the Company, no waiver shall be effective unless approved by the Board. The failure of any party hereto to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any such
provision, nor in any way to affect the validity of this Agreement or any part hereof or the right of such party thereafter to enforce each and every such provision. No waiver of any breach of or non-compliance with this Agreement shall be held to
be a waiver of any other or subsequent breach or non-compliance. 
 (e) Construction of Agreement. A reference to a Section or Exhibit
shall mean a Section in or Exhibit to this Agreement unless otherwise expressly stated. The titles and headings herein are for reference purposes only and shall not in any manner limit the construction of this Agreement which shall be considered as
a whole. The words “include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation.” 

(f) Notice. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered by hand, sent by
facsimile transmission with confirmation of receipt, sent via a reputable overnight courier service with confirmation of receipt requested, or mailed by registered or certified mad (postage prepaid and return recap requested) to the parties at the
following addresses (or at such other address for a party as shall be specified by like notice), and shall be deemed given on the date on which delivered by hand or otherwise on the date of receipt as confirmed: 

To the Company: 
 Senti
Biosciences, Inc. 
 329 Oyster Point Boulevard 3rd Floor 

South San Francisco, CA 94080 

  
 10 

 To Executive: 

Curt A. Herberts III 
 [ADDRESS]

 (g) Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws of the
State of California, without regard to its principles of conflicts of laws. 
 (h) Arbitration. To ensure the rapid and economical
resolution of disputes that might arise in connection with Executive’s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to the
enforcement or interpretation of this agreement, Executive’s employment or the termination of Executive’s employment (collectively, “Claims”), shall be resolved to the fullest extent permitted by law by final, binding, and
(to the extent permitted by law) confidential arbitration in San Francisco, CA conducted by JAMS under the then applicable JAMS employment rules. Claims subject to this arbitration provision shall (a) include, but not be limited to, Claims
pursuant to any federal, state or local law or statute, including (without limitation) the Age Discrimination in Employment Act, as amended; Title VII of the Civil Rights Act of 1964, as amended; the Americans With Disabilities Act of 1990; the
federal Fair Labor Standards Act; the California Fair Employment and Housing Act; the California Pregnancy Disability Act; and Claims pursuant to any common law, tort law or contract law, including (without limitation) breach of contract or other
promise, discrimination, harassment, retaliation, wrongful discharge, fraud, misrepresentation, defamation, and emotional distress, and (b) exclude Claims that by law are not subject to arbitration. The arbitrator shall: (a) have the
authority to compel adequate discovery for the resolution of all Claims and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision including the arbitrator s essential findings and conclusions
and a statement of the award. The Company shall pay all of the arbitrator’s fees in excess of the amount of those administrative fees Executive would have been required to pay if the Claims were decided in a court of law. Executive and the
Company acknowledge that by agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any Claims through a trial by jury or judge or by administrative proceeding. Nothing in this agreement is intended to
prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. 

(i) Remedies. Executive recognizes that money damages alone may not adequately compensate the Company in the event of breach by
Executive of this Agreement, and Executive therefore agrees that, in addition to all other remedies available to the Company at law, in equity or otherwise, the Company may be entitled to injunctive relief for the enforcement hereof. All rights and
remedies hereunder are cumulative and are in addition to and not exclusive of any other rights and remedies available at law, in equity, by agreement or otherwise. If there is a dispute between the parties regarding this Agreement, the prevailing
party in such dispute will be entitled to recover his or its reasonable attorneys’ fees and costs. 

  
 11 

 (j) Validity. In the event that any provision of this Agreement shall be determined
to be unenforceable by reason of its extension for too great a period of time or over too large a geographic area or over too great a range of activities, it shall be interpreted to extend only over the maximum period of time, geographic area or
range of activities as to which it may be enforceable. If, after application of the preceding sentence, any provision of this Agreement shall be determined to be invalid, illegal or otherwise unenforceable by an arbitrator and/or court of competent
jurisdiction, the validity, legality and enforceability of the other provisions of this Agreement shall not be affected thereby. Except as otherwise provided in this Section 17, any invalid, illegal or unenforceable provision of this Agreement
shall be severable, and after any such severance, all other provisions hereof shall remain in full force and effect. 
 (k)
Counterparts. This Agreement may be executed in one or more counterparts, all of which together shall constitute one and the same Agreement. 

* * * * * 

  
 12 

 IN WITNESS WHEREOF, the parties have caused this Employment Agreement to be executed as an
agreement under seal as of the date first written above. 
  

			
	SENTI BIOSCIENCES, INC
		
	By:	 	 /s/ Timothy Lu

	Name: Timothy Lu
	Title: CEO
	
	EXECUTIVE:
	
	 /s/ Curt A. Herberts

	Curt A. Herberts III

 Schedule A 

Prior Inventions 
 The following is a
complete list of all Prior Inventions 
             
            No Prior Inventions 

                         See
below for description of Prior Inventions 

 Exhibit A 

Form of General Release 

In exchange for good and valuable consideration, including post-employment payments of cash, I, Curt A. Herberts III
(“Releasor”) hereby irrevocably and unconditionally release, acquit and forever discharge Senti Biosciences, Inc., a Delaware corporation (the “Company”), and predecessors and successors, and each of their
respective officers, directors, stockholders, partners, members, trustees, accountants, attorneys, agents, present and former employees, (collectively referred to as the “Company Releasees”) from any and all charges, complaints,
claims, liabilities, obligations, promises, agreements, controversies, damages, actions, causes of actions, suits, rights, demands, costs, losses, damages and expenses (including attorney’s fees and costs actually incurred) of any nature
whatsoever known or unknown, suspected or unsuspected, which Releasor now has, owns or holds, or claims to have, own or hold, or which at any time heretofore, has owned or held, or claimed to have owned or held, or which Releasor at any time
hereafter may have, own or hold, or claim to have owned or held against the Company Releasees, based upon, arising out of or in connection with any circumstances, matter or state of fact up to the date of this General Release, including but not
limited to, claims or rights under any federal, state, or local statutory and/or common law in any way regulating or affecting the employment relationship, including but not limited to Title VII of the Civil Rights Act of 1964, the Age
Discrimination in Employment Act, and the Americans with Disabilities Act, and the California Fair Employment and Housing Act and the California Labor Code. THIS MEANS RELEASOR MAY NOT SUE THE COMPANY RELEASEES FOR ANY CURRENT OR PRIOR CLAIMS
ARISING OUT OF RELEASOR’S EMPLOYMENT OR ANY OTHER MATTER PRIOR TO THE DATE OF THIS RELEASE. 
 Releasor acknowledges that he has read
and understands Section 1542 of the Civil Code of the State of California, which reads as follows: 
 A general release does not
extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his settlement with the debtor. 

Releasor expressly waives and relinquishes all rights and benefits under that section and any law or legal principle of similar effect and in
any jurisdiction with respect to the release set forth herein. 
 Notwithstanding the above, it is agreed that Releasor is not releasing any
claims which cannot be released as a matter of law and is not releasing any claims for indemnification based on his contractual, statutory or other applicable indemnification rights. 

Releasor acknowledges and agrees to the following: 

(a) Releasor is obligated to return to the Company by [DATE], all Company documents, originals and copies, whether in hard or electronic
form, and all Company property, including without limitation keys, computers, computer disks, pagers, phones and credit cards. 

 (b) Releasor remains bound by, and will continue to abide by, the Sections 8, 9, 11, 12, 13,
14(d), 16 and 17 of the Employment Agreement dated as of April             , 2018, between Company and Releasor (the terms of which are incorporated by reference into this
Agreement), in addition to any other obligations created by law requiring Releasor to protect the Company’s trade secrets, and confidential and proprietary documents and information. 

(c) Releasor will not make any statements, whether verbally or in writing (including in electronic communications) that are professionally or
personally disparaging of, or adverse to the interests of, the Company or its officers, directors, managers or employees. This includes, but is not limited to, any statements that disparage the products, services, finances, financial condition,
capability or any other aspect of the business of the Company. Releasor further agrees not to engage in any conduct which is intended to harm, professionally or personally, the reputation of the Company or its officers, directors, managers or
employees. Notwithstanding the foregoing, Releasor may respond accurately and fully to any question, inquiry or request for information when required by legal process. It is understood by Releasor that the Company’s current officers will also
not disparage Releasor in any way that is professionally or personally disparaging of Releasor, and that any breach by the Company of this provision will void this paragraph. 

Releasor further acknowledges the following: 

(a) Releasor has read this Release carefully and understands all of its terms. 

(b) Releasor understands that, among other claims, Releasor is releasing any claims against the Company alleging discrimination on the basis of
age. 
 (c) Release acknowledges that Releasor has been advised and encouraged to consult with legal counsel for the purpose of reviewing the
terms of this Release. 
 (d) Releasor has been given twenty-one (21) days in which to consider this Release and whether to accept it.
If Releasor chooses to sign this Release within that time. Releasor is requested to sign and date below and return it to Senti Biosciences, Inc, 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080. 

(e) Even after executing this Release, Releasor has seven (7) days after signing to revoke this Release. The Release will not be effective
or enforceable until this seven (7) day period has expired. In order to revoke my assent to this Release, Releasor must, within seven (7) days after Releasor signs this Release, deliver a written notice of rescission to the above-named
individual at the address noted above. To be effective, the notice of rescission must be hand delivered, or postmarked within the seven (7) day period and sent by certified mail, return receipt requested, to the referenced address. 

 IN WITNESS WHEREOF, the said Curt A. Herberts III has executed this General Release
under seal on this              day of [MONTH, YEAR]. 
  

	
	  

	Curt A. Herberts III

 Witnessed:EX-10.9

 Exhibit 10.9 

May 13, 2021 
 Deborah Knobelman 

VIA EMAIL 
  

	Re:	 Offer of Employment 

Dear Deborah: 
 Senti Biosciences, Inc. (the
“Company”) is pleased to offer you employment as the Company’s Chief Financial Officer (“CFO”) on the terms and conditions set forth in this letter agreement (the
“Agreement”). 
 1. Commencement of Employment. Your employment with the Company will commence
on May 18, 2021 (the “Effective Date”). 
 2. Duties. As CFO, you will serve as Principal
Accounting Officer (PAO) and Principal Financial Officer (PFO). You will be responsible for Investor Relations, Risk Management, Finance and Accounting, reporting to the Chief Executive Officer. You shall devote your best efforts and full business
time, skill and attention to the performance of your duties. You will be expected to adhere to the general employment policies and practices of the Company that may be in effect from time to time, except that when the terms of this Agreement
conflict with the Company’s general employment policies or practices, this Agreement will control. You will work out of your home in Denver, Colorado, and will travel to the Company’s offices in South San Francisco, California as needed.
The company will not require you to relocate permanently to San Francisco, California and shall reimburse you for all reasonable and properly documented travel expenses between Denver and San Francisco, including airfare, ground transportation,
lodging, and meals. The Company may change your position, duties, and compensation from time to time at its discretion, subject to the terms and conditions set forth herein, specifically in reference to the terms set forth in Section 7(d).

 3. Compensation. 

(a) Base Salary. You will be paid an annual base salary of $400,000, less applicable deductions and withholdings, payable in accordance
with the Company’s payroll practices as may be in effect from time to time. Your base salary shall be reviewed annually by the Company’s Board of Directors (the “Board”), commencing in January 2022. 

(b) Signing Bonus. The Company will pay you a signing bonus of $40,000. This bonus will be paid within ninety (90) days after the
Effective Date, less deductions and withholdings. Although this bonus will be paid at the time of hire, it will not be earned until you have completed fourteen (14) months of employment. Therefore, in the event you resign your employment with
the Company without Good Reason (as defined herein) before you complete fourteen (14) months of employment with the Company, then you will be required to repay the entire amount of this bonus to the Company within thirty (30) days after
your last day of employment. 

 (c) Annual Performance Bonus. Each year, you will be eligible to earn an annual
performance bonus with an annual target amount of up to 40% of your annual base salary, less applicable payroll deductions and withholdings (the “Annual Bonus”) (to be prorated for 2021 based on the Effective Date). Whether
you receive such a bonus, and the amount of any such bonus, shall be determined by the Board in its sole discretion, and shall be based upon achievement of Company and individual performance objectives, with such goals and the attainment of such
goals to be determined by the Company in its sole discretion. No amount of the Annual Bonus is guaranteed, and you must be an employee on the last day of the applicable calendar year in order to earn an Annual Bonus. Therefore, subject to
Section 7 of this Agreement, if your employment is terminated either by you or the Company for any reason prior to the end of the calendar year, you will not have earned the Annual Bonus and no partial or prorated Annual Bonus will be paid. The
Annual Bonus, if earned, will be paid within 90 days following the completion of the applicable bonus year. 
 4. Benefits. Subject to
any contributions generally required of employees of the Company, commencing on the Effective Date, you shall be entitled to participate in any and all employee benefit plans from time to time in effect for full-time executive employees of the
Company. Such participation shall be subject to the terms of the applicable plan documents and generally applicable Company policies. Additional information regarding these benefits is available for your review upon request. The Company may, from
time to time, change these benefits in its discretion. 
 5. Equity. Subject to approval by the Board, the Company will grant
you an option to purchase 750,000 shares of the Company’s common stock (the “Option”). The Option shall vest over a four-year period, with one quarter (1/4) of the shares subject to the Option vesting
on the first anniversary of the Effective Date, and the remaining shares vesting equally over the following thirty-six (36) months of continuous service. The Option shall be issued pursuant to the terms and conditions of the Company’s
Equity Incentive Plan (the “Plan”), at an exercise price equal to 100% of the fair market value of the Company’s common stock on the grant date, as provided in the Plan and consistent with the requirements
for an exemption from the application of Section 409A of the Internal Revenue Code (the “Code”) and shall be governed in all respects by the terms of the Plan, the grant notices and the option
agreements. 
 6. Expenses. The Company shall pay or reimburse you for all reasonable business expenses incurred or paid by you
in connection with your employment by the Company in accordance with the Company’s policies in effect from time to time. 
 7.
At Will Employment; Severance Benefits. 
 (a) At-Will Employment. Your employment with the Company will be
“at- will.” This means that either you or Company may terminate your employment at any time, with or without Cause (as defined herein), and with or without advance notice. Upon termination of your employment for any reason, the Company
shall pay you all earned but unpaid salary, and all accrued but unused vacation earned by you through and including the employment termination date, subject to required payroll deductions, in accordance with governing law. You will not be eligible
to receive any severance benefits, except as expressly provided in this Agreement. 

 (b) Termination for Cause; Death; Disability; Resignation Without Good Reason. If, at
any time, the Company terminates your employment for Cause, or if either party terminates your employment as a result of your death or disability, or if you resign without Good Reason (as defined herein), you will receive the accrued amounts set
forth in Section 7(a) and will not be entitled to any other form of compensation from the Company, including any severance benefits. 

(c) Termination Without Cause or Resignation for Good Reason Outside of Change of Control Period. If at any time outside of a Change of
Control Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, provided such termination or resignation constitutes a Separation from Service (as defined under Treasury Regulation
Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”), then subject to your compliance with the terms of this Agreement and subject to the preconditions set forth in
Section 7(e), the Company will provide you with the following severance benefits (the “Severance Benefits”): 

(i) Cash Severance. You will receive cash severance equal to nine (9) months of your then current base salary. This severance will
be paid in equal installments on the Company’s regular payroll schedule over the 9-month period following your Separation from Service and will be subject to applicable tax withholdings; provided, however, that no payments will be made prior to
the 60th day following your Separation from Service (and with the first such payment including any amounts accrued following such Separation from Service). 

(ii) COBRA Severance. If you timely elect continued coverage under COBRA, the Company will continue to pay the cost of your health care
coverage in effect at the time of your employment termination for a maximum of nine (9) months. The Company’s obligation to pay these amounts on your behalf will cease if you obtain health care coverage from another source (e.g., a new
employer or spouse’s benefit plan), unless otherwise prohibited by applicable law. Notwithstanding the above, if the Company determines in its sole discretion that it cannot provide these benefits without potentially violating applicable law
(including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the monthly COBRA premium that you would be required to pay to
continue your group health coverage in effect on the date of your termination (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made on the last day of each month regardless of whether you
elect COBRA continuation coverage and shall end on the earlier of (x) the date upon which you obtain other employment or (y) the same date as (when your COBRA began) of the 9th calendar month following your Separation from Service. 

(d) Termination Without Cause or Resignation for Good Reason During Change of Control Period. If at any time during a Change of Control
Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, provided such termination or resignation constitutes a Separation from Service, then subject to your compliance with the terms of this
Agreement and subject to the preconditions set forth in Section 7(e), the Company will provide you with the following severance benefits: 

 (i) Cash Severance. You will receive cash severance equal to twelve (12) months
of your then current base salary, paid in a lump sum, subject to applicable tax withholdings, on the 60th day following your Separation from Service. 

(ii) Bonus Severance. You will receive an additional cash severance payment, less applicable deductions and withholdings, equal to the
amount of your target annual bonus for the calendar year in which your employment is terminated, paid in a lump on the 60th day following your Separation from Service. 

(iii) COBRA Severance. If you timely elect continued coverage under COBRA, the Company will continue to pay the cost of your health
care coverage in effect at the time of your employment termination for a maximum of eighteen (18) months. The Company’s obligation to pay these amounts on your behalf will cease if you obtain health care coverage from another source (e.g.,
a new employer or spouse’s benefit plan), unless otherwise prohibited by applicable law. Notwithstanding the above, if the Company determines in its sole discretion that it cannot provide these benefits without potentially violating applicable
law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the monthly COBRA premium that you would be required to pay to
continue your group health coverage in effect on the date of your termination (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made on the last day of each month regardless of whether you
elect COBRA continuation coverage and shall end on the earlier of (x) the date upon which you obtain other employment or (y) the same date as (when your COBRA began) of the eighteenth calendar month following your Separation from Service.

 (iv) Accelerated Vesting. The Company will accelerate the vesting of your equity awards such that you will be deemed fully vested
in all such shares as of your Separation from Service. 
 (e) Conditions to Receipt of Severance. Your receipt of the severance
benefits set forth in this Section 7 is conditioned upon: (i) you continuing to comply with your obligations under your Confidential Information and Inventions Agreement; and (ii) you delivering to the Company an effective, general
release of claims in favor of the Company substantially in the form attached hereto as Exhibit A (the “Release”) within the applicable time period set forth therein. 

8. Definitions. 

(a) Cause. For purposes of this Agreement, “Cause” shall mean the occurrence of any of the following:
(i) your material breach of this Agreement, (ii) any act or omission by you that has a material and adverse effect on the Company’s business, or on your ability to perform services for the Company, including, without limitation, the
commission of any crime (other than minor traffic violations), or (iii) your material misconduct or material neglect of your duties in connection with the business or affairs of the Company; provided, however, that
before terminating your employment for Cause, the Company will provide you with 30 days’ advance written notice with the event specifically set forth in the notice and the opportunity to cure the event (if curable). 

 (b) Change of Control. For purposes of this Agreement, a “Change of
Control” shall mean the closing of: (i) a sale of all or substantially all of the assets of the Company; (ii) any consolidation or merger of the Company with or into any other corporation or other entity or person, or any
other corporate reorganization, other than any such consolidation, merger or reorganization in which the stockholders of the Company immediately prior to such consolidation, merger or reorganization, continue to hold a majority of the voting power
of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization; or (iii) a stock tender or a merger, consolidation or similar event pursuant to a
transaction or series of related transactions in which a third party (which term shall include a current stockholder) acquires more than fifty percent (50%) of the equity voting securities of the Company outstanding immediately prior to the
consummation of such transaction or series of related transactions, and the shareholders of the Company do not retain a majority of the equity voting securities of the surviving entity, other than (a) a merger, conversion or other transaction
the principal goal of which is to change the jurisdiction of incorporation of the Company, or (b) an equity security financing for the account of the Company in which capital stock of the Company is sold to one or more institutional investors.
Notwithstanding the foregoing, a transaction or series of transactions shall not constitute a Change of Control unless such transaction or series of transactions also qualifies as a “change in control” event under U.S. Treasury Regulation
1.409A-3(i)(5). 
 (c) Change of Control Period. For purposes of this Agreement, a “Change of Control Period”
is defined as the period commencing three (3) months prior to the effective date of a Change of Control and ending on the twelve (12) month anniversary of the effective date of a Change of Control. 

(d) Good Reason. For purposes of this Agreement, “Good Reason” shall mean your resignation because of any of the
following actions taken without your consent: (i) the Company’s material breach of any one or more of the material provisions of this Agreement; (ii) a material reduction by the Company of your annual base salary, unless such
reduction is applied equally, as a percentage of base salary, to all senior executives of the Company; or (iii) a material adverse change in your duties, authority, or responsibilities relative to your duties, authority, or responsibilities in
effect immediately prior to such reduction (other than a change in title and provided that a change in title, reporting lines or position in connection with a Change of Control will not, in itself, be deemed to be a change in duties, authority or
responsibility); provided, however, that any such termination by you shall only be deemed for Good Reason pursuant to this definition if: (1) you give the Company written notice of your intent to terminate for Good Reason within ninety
(90) days following the first occurrence of the condition(s) that you believe constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s) within thirty (30) days
following receipt of the written notice (the “Cure Period”); and (3) you voluntarily terminate your employment within thirty (30) days following the end of the Cure Period. 

 9. Section 409A. It is intended that all of the severance benefits and other
payments payable under this letter satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this letter will be
construed to the greatest extent possible as consistent with those provisions. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), your right to receive any
installment payments under this letter (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be
considered a separate and distinct payment. Notwithstanding any provision to the contrary in this letter, if you are deemed by the Company at the time of your Separation from Service to be a “specified employee” for purposes of Code
Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be “deferred compensation”, then to the extent delayed commencement of
any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to you prior to the earliest
of (i) the expiration of the six-month period measured from the date of your Separation from Service with the Company, (ii) the date of your death or (iii) such earlier date as permitted under Section 409A without the imposition
of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining payments
due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. 
 10.
280G. 
 (a) If any payment or benefit you will or may receive from the Company or from another source (a “280G
Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise
Tax”), then any such 280G Payment pursuant to this letter agreement (a “Payment”) will be equal to the Reduced Amount. The “Reduced Amount” will be either (x) the largest portion of the Payment that would result in no
portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking
into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit
notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding
sentence, the reduction will occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be
reduced pro rata (the “Pro Rata Reduction Method”). 
 (b) Notwithstanding any provision of paragraph (a) to the
contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the
Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification will preserve to the greatest
extent possible, the greatest economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), will be reduced (or eliminated) before
Payments that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not
deferred compensation within the meaning of Section 409A of the Code. 

 (c) If you receive a Payment for which the Reduced Amount was determined pursuant to
clause (x) of Section 10(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you agree to promptly return to the Company a sufficient amount of the Payment (after
reduction pursuant to clause (x) of Section 10(a)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of
Section 10(a), you will have no obligation to return any portion of the Payment pursuant to the preceding sentence. 
 11.
Confidentiality Obligations. As condition of your employment, you must sign and abide by the Company’s standard form of Employee Confidential Information and Invention Assignment Agreement, a copy of which is attached hereto as
Exhibit B. 
 12. Arbitration. To ensure the timely and economical resolution of disputes that may arise between you and
the Company, both you and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by applicable law, you will submit solely to final, binding and confidential arbitration any
and all disputes, claims, or causes of action arising from or relating to: the negotiation, execution, interpretation, performance, breach or enforcement of this letter agreement; or your employment with the Company (including but not limited to all
statutory claims); or the termination of your employment with the Company (including but not limited to all statutory claims). BY AGREEING TO THIS ARBITRATION PROCEDURE, BOTH YOU AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A
TRIAL BY JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING. The Arbitrator will have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this section and to determine any
procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition. All claims, disputes, or causes of action under this section, whether by you or the Company, must be brought solely in an
individual capacity, and will not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The Arbitrator may not
consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences in this paragraph are found to violate applicable law or are otherwise
found unenforceable, any claim(s) alleged or brought on behalf of a class will proceed in a court of law rather than by arbitration. Any arbitration proceeding under this Arbitration section will be presided over by a single arbitrator and conducted
by JAMS, Inc. (“JAMS”) in San Francisco, CA under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at
http://www.jamsadr.com/rules-employment-arbitration/). You and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party’s own expense. The Arbitrator will: (a) have the authority to
compel adequate discovery for the resolution of the dispute; (b) issue a written arbitration decision, to include the arbitrator’s essential findings and conclusions and a statement of the award; and (c) be authorized to award any or
all remedies that you or the Company would be entitled to seek in a court of law. The Company will pay all JAMS arbitration fees in excess of the amount of court fees that would be required of you if the dispute were decided in a court of law. This
section will not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the
California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the
Federal Arbitration Act or otherwise invalid (collectively, the “Excluded Claims”). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while
any other claims will remain subject to mandatory arbitration. Nothing in this section is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such
arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly. 

 13. Miscellaneous. This Agreement, including its exhibits, is the complete and
exclusive statement of all of the terms and conditions of your employment with the Company, and supersedes and replaces any and all prior agreements or representations with regard to the subject matter hereof, whether written or oral. It is entered
into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified, amended or extended except in a writing signed by you and a duly authorized member of the Board. This Agreement is
intended to bind and inure to the benefit of and be enforceable by you and the Company, and our respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights hereunder without the
express written consent of the Company. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal
or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and
enforced as if such invalid, illegal or unenforceable provisions had never been contained herein. This Agreement and the terms of your employment with the Company shall be governed in all aspects by the laws of the State of California. 

 This offer is subject to satisfactory proof of your right to work in the United States and satisfactory
completion of a Company-required background check. If you agree to the terms and conditions set forth herein, please sign below. 
 If you have any
questions about this Agreement, please do not hesitate to call me. 
 Best regards, 

/s/ Timothy Lu 
 Timothy Lu, M.D., Ph.D. 

Co-founder and Chief Executive Officer 

UNDERSTOOD, ACCEPTED AND AGREED TO: 

 

					
	 /s/ Deborah Kobelman

Deborah Knobelman
	 	                     

	  	  
 Date

 EXHIBIT A - FORM OF RELEASE 

(TO BE SIGNED ON OR WITHIN 21 DAYS OF SEPARATION DATE) 

I understand that my employment with SENTI BIOSCIENCES, INC. (the “Company”) has terminated. The Company
has agreed that if I sign this Release, the Company will provide me with the benefits set forth in the offer letter agreement (the “Agreement”) between me and the Company. I understand that I am not entitled to
such severance benefits unless I sign this Release without revocation. I also understand that, regardless of whether I sign this Release, the Company will pay me all of my accrued salary and vacation through my last day of employment, to which I am
entitled by law. 
 I hereby generally release the Company and its officers, directors, agents, attorneys, employees, stockholders,
parents, subsidiaries, and affiliates from any and all claims, liabilities, demands, causes of action, attorneys’ fees, damages, or obligations of every kind and nature, whether they are now known or unknown, arising at any time prior to the
date I sign this Release. This general release includes, but is not limited to: (i) all federal and state statutory and common law claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims
arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), the federal Employee
Retirement Income Security Act of 1974 (as amended), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended); (ii) claims related to my employment or the termination of my employment; and
(iii) claims related to breach of contract, tort, wrongful termination, discrimination, wages or benefits, or claims for any form of equity or compensation. 

I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA. I also acknowledge that the consideration given
for the waiver in this paragraph is in addition to anything of value to which I was already entitled. I have been advised by this writing, as required by the ADEA that: (a) my waiver and release do not apply to any claims that may arise after
my signing of this Release; (b) I should consult with an attorney prior to executing this Release; (c) I have twenty-one (21) days within which to consider this Release (although I may choose to voluntarily execute this Release
earlier); (d) I have seven (7) days following the execution of this release to revoke the Release; and (e) this Release will not be effective until the eighth day after this Release has been signed by me. 

Notwithstanding the release in the preceding paragraphs, I am not releasing: (i) any right of indemnification I may have under contract or
law; (ii) any rights that cannot be waived as a matter of law; and (iii) claims for breach of this Release. In addition, I understand that nothing in this Release limits my ability to file a charge or complaint with the Equal Employment
Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission
(“Government Agencies”). I further understand that this Release does not limit my ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any
Government Agency, including providing documents or other information, without notice to the Company. While this Release does not limit my right to receive an award for information provided to the Securities and Exchange Commission, I
understand and agree that, to maximum extent permitted by law, I am otherwise waiving any and all rights I may have to individual relief based on any claims that I have released and any rights I have waived by signing this Release. 

 In releasing claims unknown to me at present, I am waiving all rights and benefits under Section 1542
of the California Civil Code, and any law or legal principle of similar effect in any jurisdiction: “A general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his favor at the time of
executing the release, which if known by him would have materially affected his settlement with the debtor or released party.” 
 I hereby represent
that I have been paid all compensation owed and for all hours worked, I have received all the leave and leave benefits and protections for which I am eligible, and I have not suffered any on- the-job injury for which I have not already filed a
workers’ compensation claim. 
 I hereby confirm my obligations under my Confidential Information and Inventions Assignment Agreement with the Company.

 I also agree that I will not voluntarily (except in response to legal compulsion) assist any person in bringing or pursuing any proposed or pending
litigation, arbitration, administrative claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents. I further agree to reasonably cooperate with the Company by
voluntarily providing accurate and complete information, in connection with the Company’s actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters, arising from events,
acts, or failures to act that occurred during the period of my employment by the Company. 
 I hereby agree not to disparage the Company, or its
officers, directors, employees, shareholders or agents, in any manner likely to be harmful to them or their business, business reputation, or personal reputation; provided, however, that I will respond accurately and fully to any
question, inquiry or request for information when required by legal process or in connection with a government investigation. 
  

	
	Dated:
                                         
                               
	
	                                      
                                         
     
	Deborah Knobelman

 EXHIBIT B 

CONFIDENTIAL INFORMATION AND INVENTION AGREEMENT 

(TO BE SENT SEPARATELY)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]